Ohio State Board of Pharmacy February 2026 Update Sets State-Level Peptide Compounding Guardrails Alongside Federal 503A Rules
The Ohio State Board of Pharmacy released a February 18, 2026 update to its peptide compounding guidance establishing state-specific requirements that layer on top of federal 503A rules. The Ohio guidance requires all compounded peptides to be prepared pursuant to a valid patient-specific prescription from an Ohio-licensed practitioner, with detailed prescription documentation and provider-verification protocols; pharmacies cannot compound peptides on the FDA list of substances withdrawn for safety or effectiveness reasons. The guidance followed late-2025 and early-2026 enforcement actions in which at least three Ohio pharmacies received consent agreements and fines for peptide compounding violations. Together with the Alabama Board of Medical Examiners' May 26 notice prohibiting non-FDA-approved peptide prescribing, Ohio's update establishes a clear state-level enforcement pattern ahead of the July 23-24 PCAC meeting.